Chemogenomics.
In plain English
AI plain-English summaryA private company’s trove of drug-discovery data is moving to a public database, giving academic researchers free access to information that was previously locked behind commercial walls. These pharmacological structure-activity-relationship (SAR) data describe how drug-like molecules interact with their biological targets. Until now, academic labs could only find such data piecemeal in the literature or buy it from commercial vendors, which has held back their ability to engage in effective drug discovery. Without this resource, many promising target-compound relationships remain unexplored outside industry. The team will transfer the data to the European Bioinformatics Institute, build a searchable database, and provide web access, programmatic interfaces, and downloads. They will also establish a curation pipeline and integrate the data with other biological resources at EBI. Training programmes will help academic scientists exploit the data for translational research. If successful, this resource could accelerate target identification for all diseases—including neglected tropical diseases that lack commercial markets—enable knowledge-based lead optimisation, and improve the design of chemical libraries. In the longer term, it could also support better predictive toxicology, quietly strengthening the drug-development infrastructure that underpins modern medicine.
View original technical description
View the original record at the funder ↗
Researchers
Related Research
Grants with similar aims, by meaning.
Original classification
Strategic Award - SciencePlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know